Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascot, catch up on our reading, take a few naps as often as possible, and tend to the Pharmalot grounds. And what about you? This is a fine time to enjoy the great outdoors or engage in a seasonal ritual — uncluttering your castle. You could indulge in a little binge-watching on the telly or reach out to someone who is feeling a bit isolated these days. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

Medicare finalized its plan to restrict coverage for the controversial, pricey Alzheimer’s treatment Aduhelm to patients participating in clinical trials, STAT tells us. The decision marks the end of an intense pressure campaign from drugmakers and some patient groups that wanted Medicare to reverse its initial proposal and pay for the drug for more patients. As clinical trials are usually run out of major medical centers, the decision will likely mean some interested patients will not be able to access the drug. However, Medicare is not explicitly requiring that patients be treated at hospital-based clinics as the initial proposal stated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment